UFA
SVA

US Financial Advisors’s Sinovac Biotech, Ltd SVA Stock Holding History

US Financial Advisors’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-500
Closed -$3K – 669
2015
Q4 		$3K Hold
500
– – ﹤0.01% 445
2015
Q3 		$3K Buy
+500
New +$2.65K 0.01% 380

Other funds holding SVA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

US Financial Advisors's SVA Position: Q1 2016 in Review

US Financial Advisors sold out of Sinovac Biotech, Ltd (SVA) in Q1 2016, closing a stake of 500 shares — an estimated $3K sold.

US Financial Advisors first reported a position in SVA in Q3 2015 and held it in 2 quarters. The position peaked at $3K in Q4 2015. 34 funds tracked by Wall St. Rank hold SVA as of Q1 2016.

  • US Financial Advisors reported no remaining Sinovac Biotech, Ltd position as of Q1 2016 after selling out during the quarter.
  • US Financial Advisors sold 500 Sinovac Biotech, Ltd shares in Q1 2016, an estimated $3K.
  • US Financial Advisors first reported a position in Sinovac Biotech, Ltd in Q3 2015 and held it in 2 quarters.
  • US Financial Advisors's Sinovac Biotech, Ltd position peaked at $3K in Q4 2015.
  • 34 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q1 2016.

Based on US Financial Advisors's 13F filing for Q1 2016, filed 5 May 2016.